Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 4

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 4
---
 on Form S-1 (Registration No. 333-278512), which was subsequently declared effective by the SEC on April 15, 2024 (the “April 2024 Registration Statement”), relating to the resale from time to time of up to 1,632,000 shares of Common Stock by the selling stockholders identified therein, including their pledgees, assignees, donees, transferees or their respective successors-in-interest consisting of: (i) 1,600,000 shares of Common Stock issuable upon the exercise of common warrants to purchase shares of Common Stock (the “March 2024 Common Warrants”) purchased in a private placement transaction (the “March 2024 Private Placement”), pursuant to the terms of a Securities Purchase Agreement, dated as of March 6, 2024 (the “March 2024 Purchase Agreement”), between us and the investors listed on the signature pages thereto (the “March 2024 Investors”), and (ii) 32,000 shares of Common Stock issuable upon the exercise of warrants (the “March 2024 PA Warrants” and, together with the March 2024 Common Warrants, the “March 2024 Warrants”) issued to designees of WallachBeth Capital LLC (“WallachBeth”) as partial compensation for WallachBeth acting as placement agent in connection with the March 2024 Private Placement. The March 2024 Private Placement closed on March 8, 2024. As of June 27, 2025, March 2024 Warrants to purchase 565,333 shares of Common Stock remain outstanding and unexercised.

On September 11, 2024, we filed a Registration Statement on Form S-1 (Registration No. 333-282045), which was subsequently declared effective by the SEC on September 19, 2024 (the “September 2024 Registration Statement”), relating to the resale from time to time of up to 1,801,944 shares of Common Stock by the selling stockholders identified therein, including their pledgees, assignees, donees, transferees or their respective successors-in-interest consisting of: (i) 450,000 shares of Common Stock issuable upon the exercise of common warrants to purchase shares of Common Stock (the “August 2024 Common Warrants”) purchased by an institutional investor (the “August 2024 Investor”) in a private placement transaction (the “August 2024 Private Placement”) pursuant to